

Agenda

Measure Applications Partnership Dual Eligible Beneficiaries Workgroup Web Meeting April 30, 2013 1:00 pm - 3:00 pm ET

Participant Instructions:

- Please log in 15 minutes prior to the scheduled start to allow time for troubleshooting
- Direct your web browser to: <u>http://nqf.commpartners.com</u> for slides and streaming audio
- Under "Enter a Meeting," type in the meeting number 994737 and click "Enter"
- In the "Display Name" field, type in your first and last name and click "Enter Meeting"
- Public attendees dial (855) 452-6871; use conference ID code 34575141 to access the audio platform.

Meeting Objectives:

- Begin work on measures for dual eligible beneficiaries disabling behavioral and cognitive conditions
- Prepare for in-person meeting by introducing the approach for creating a family of measures
- Review public comments received on December 2012 Interim Report and discuss how to address them going forward
- Develop understanding of the quality issues facing beneficiaries with disabling behavioral and cognitive conditions and the opportunities for improvement through measurement

1:00 pm Welcome

Alice Lind, MAP Dual Eligible Beneficiaries Workgroup Chair Cheryl Powell, Centers for Medicare & Medicaid Services (CMS)

- Prior accomplishments and current priorities
- Reflections from CMS

1:10 pm How Will the Pieces Fit Together?

Alice Lind

• Review the Evolving Core Set of Measures for Dual Eligible Beneficiaries and measures for high-need subgroups as inputs for a family of measures

FAGE 2	
	 Review public comments received on December 2012 Interim Report Discussion and questions
1:35 pm	What Is Known about Quality Issues for Dual Eligible Beneficiaries with Disabling Behavioral and Cognitive Conditions?
	Amaru Sanchez, Project Analyst, NQF Megan Duevel Anderson, Project Analyst, NQF
	 Serious mental illness (SMI) Substance use disorders (SUD) Intellectual/developmental disabilities Dementia and other acquired cognitive impairments
2:00 pm	State of Performance Measures for Behavioral Health
	Alice Lind Harold Pincus, NQF Behavioral Health Steering Committee Co-Chair and MAP Coordinating Committee Member Mady Chalk, NQF Behavioral Health Steering Committee Member and MAP Dual Eligible Beneficiaries Workgroup Subject Matter Expert: Substance Use
	 SAMHSA quality framework NQF's behavioral health measure endorsement project and related measure development efforts Additional inputs and information from workgroup members
2:35 pm	Key Issues for Measurement
	Sarah Lash, Senior Program Director, NQF
	 Discuss proposed key issues Strategy to identify measures for behavioral health sub-populations
2:45 pm	Opportunity for Public Comment
2:55 pm	Summary and Next Steps
	Alice Lind
	Preview goals for the May 21-22 in-person meeting
3:00 pm	Adjourn

PAGE 2





American Association on Intellectual and Developmental Disabilities	Margaret Nygren, EdD
American Federation of State, County and Municipal Employees	Sally Tyler, MPA
American Geriatrics Society	Jennie Chin Hansen, RN, MS, FAAN
American Medical Directors Association	Gwendolen Buhr, MD, MHS, MEd, CMD
Center for Medicare Advocacy	Alfred Chiplin, JD, M.Div.
Consortium for Citizens with Disabilities	E. Clarke Ross, DPA
Humana, Inc.	George Andrews, MD, MBA, CPE, FACP, FACC, FCCP
L.A. Care Health Plan	Laura Linebach, RN, BSN, MBA
National Association of Public Hospitals and Health Systems	Steven Counsell, MD
National Association of Social Workers	Joan Levy Zlotnik, PhD, ACSW
National Health Law Program	Leonardo Cuello, JD
National PACE Association	Adam Burrows, MD
SNP Alliance	Richard Bringewatt

Substance Abuse	Mady Chalk, MSW, PhD
Disability	Anne Cohen, MPH
Emergency Medical Services	James Dunford, MD
Measure Methodologist	Juliana Preston, MPA
Home & Community Based Services	Susan Reinhard, RN, PhD, FAAN
Mental Health	Rhonda Robinson-Beale, MD
Mental Health	KIIOIIua KUUIIISUII-Beale, MD
Nursing	Gail Stuart, PhD, RN
Nursing Federal Government Members	Gail Stuart, PhD, RN
Nursing Federal Government Members gency for Healthcare Research and Quality	Gail Stuart, PhD, RN
Nursing Federal Government Members agency for Healthcare Research and Quality IMS Federal Coordinated Healthcare Office	Gail Stuart, PhD, RN D.E.B. Potter, MS Cheryl Powell
Nursing Federal Government Members Igency for Healthcare Research and Quality	Gail Stuart, PhD, RN
Nursing Federal Government Members Agency for Healthcare Research and Quality CMS Federal Coordinated Healthcare Office Health Resources and Services Administration	Gail Stuart, PhD, RN D.E.B. Potter, MS Cheryl Powell Samantha Meklir, MPP

Meeting Objectives

- Begin work on measures for dual eligible beneficiaries with disabling behavioral/cognitive conditions
- Prepare for in-person meeting by introducing the approach for creating a family of measures
- Review public comments received on December 2012 Interim Report and discuss how to address them going forward
- Develop understanding of the quality issues facing high-need beneficiaries and the opportunities for improvement through measurement

Measure Applications Partnership CONVENED BY THE NATIONAL QUALITY FORUM

> Dual Eligible Beneficiaries Workgroup Vision for High-Quality Care

In order to promote a system that is both sustainable and person- and family-centered, individuals eligible for both Medicare and Medicaid should have timely access to appropriate, coordinated healthcare services and community resources that enable them to attain or maintain personal health goals.

October 201				
Phase 1 Interim Report Strategic Approach	June 2012 Phase 1 Final Report	December 2	012 July 2013	
to Performance Measurement for Dual Eligible Beneficiaries	Core Set of Measures for Dual Eligible Beneficiaries	Phase 2 Interim Report Evolving Core Set of Measures Specialized Measures for High- Need Subgroups	Phase 2 "Preliminary Findings" Behavioral Health Subgroups Family of Measures for Dual Eligible Beneficiaries	Future Phase 2 Final Report Commenting Coordinating Committee Review



























What Is Known about Quality Issues for Dual Eligible Beneficiaries with Disabling Behavioral /Cognitive Conditions?











Interactions Between SMI and Substance Use

- In 2011, adults with any type of mental illness were more likely than adults who did not have mental illness to use illicit drugs (25.2% vs. 11.8%), smoke cigarettes (34.7% vs. 20.9%), and binge drink (27.6% vs. 23.5%).
 - Adults with SMI used substances to an even greater extent (illicit drug use 31.3%, heavy alcohol use 8.7%, and cigarette use 44.4%).
- Among the 18.9 million adults with SUD, 42.3% had co-occurring mental illness.
 - Of adults with SMI, 17.5% had alcohol dependence or abuse, 22.6% also had substance dependence or abuse and 9.9% also met the criteria for illicit drug dependence or abuse.
 - Co-occurring mental illness and substance abuse was more common in: adults ages 18-25, adult males, the unemployed, and adults living in poverty.
 - 31% of adults using homeless services reported having a combination of mental health and addition disorders.
 - Among adults who had a past year with both SMI and SUD, only 65.6% received mental health care or specialty substance use treatment.

Measure Applications Partnership SAMHSA, Results from the 2011 National Survey on Drug Use and Health: Mental Health Findings, http://www.samhsa.gov/data/NSDUH/2k11MH FindingsandDetTables/2K11MHFR/NSDUHmhfr2011.pdf, NAMI, Mental 2 Ullness: Facts and Numbers 2

Profile: Beneficiary with SMI Diagnosis and Substance Use Disorder Richard, a 42 year old dual eligible beneficiary . diagnosed with bipolar disorder and who experiences paranoid episodes Poor medication adherence Divorced and estranged from his adult children and other family Regular smoker with untreated illicit drug use Emergency room visit resulted in diagnosis of diabetic neuropathy and surgery for foot amputation Currently resides in subsidized housing and will need additional assistance Measure Applications Partnership 28 CONVENED BY THE NATIONAL QUALITY FORUM

Burden of Acquired Cognitive Impairments on Dual Eligible Beneficiaries

- Dementia is the loss of cognitive functioning thinking, remembering, and reasoning – and behavioral abilities to such an extent that it interferes with a person's daily life and activities.
 - Most commonly caused by Alzheimer's disease and vascular dementia
 - 28.1% of dual beneficiaries 65+ had dementia, compared to 8.2% of Medicare only and 4% of Medicaid only beneficiaries.
 - In 2010, 20% of dual eligible beneficiaries had Alzheimer's (vs. 9% of Medicare FFS beneficiaries)
 - Approximately 50% of dual beneficiaries 65+ with SMI also had a diagnosis of dementia.
 - The risk of developing Dementia is 2 to 6 times greater for people with Parkinson's disease, a condition more common among dual beneficiaries.
- Alzheimer's and Parkinson's diseases are among the most costly conditions for dual eligible beneficiaries.

Convented by THE NATIONAL QUALITY FORUM



Profile: Beneficiary with ID/DD and Acquired Cognitive Impairment

- Samuel, 56 y/o male with Down Syndrome
- Lives with his elderly mother
- Increasing short-term memory loss
- Difficulty doing complex tasks requiring multiple steps
- Reduced interest in being sociable and enthusiasm for usual activities
- Diagnosis of early stages of dementia

Measure Applications Partnership CONVENED BY THE NATIONAL QUALITY FORUM



31

32

State of Performance Measures for Behavioral Health





























47

Themes Going Forward in Developing Behavioral Health Measures

- Measurement-Based Care
- Integration of Behavioral and General Health Care
- Shared Accountability
- Recovery- Based Care
- Linkage with Social Services and Education
- Quality of Care in Correctional Institutions
- Structural Measures for "Evidence-Based Behavioral Health Care Homes"









Common Issues Across High-Need Subgroups	SMI	es: Quality of	Dementia/Acquired Impairments	ID/DD
Preventing abuse and neglect (specifically in institutional settings) Maintaining or improving functional status Shared decision- making Respect for personal preferences	Improving personal independence and self-direction	Withdrawal management Maintaining or improving functional status Decision support/shared- decision making	Rehabilitation and redevelopment of functional skills Improving or maintaining personal independence and self-direction Social engagement and involvement in meaningful activities	Habilitation and development of key functional and personal skills Engagement and participation in healthy activities Improving or maintaining persona independence and self-direction Physical accessibility and mobility Maintaining or improving functional status

Common Issues Across High-Need Subgroups	SMI	SUD	Dementia/Acquired Impairments	ID/DD
Avoidable admissions, readmissions, complications Person-centered care planning Care transitions, discharge olanning Communication between providers Communication between providers and beneficiaries Cultural competence Medication management: access, appropriateness, reconciliation, adherence Adverse drug events	Use of physical restraints Suicide prevention	Suicide prevention	Use of physical restraints Advance care planning	Use of physical restraints

Common Issues Across High-Need Subgroups	SMI	SUD	Dementia/Acquired Impairments	ID/DD
Oral Health Nutrition and weight management New or worsening chronic conditions, especially cardiometabolic diseases	Broad screening for SMIs Screening for substance use and/or risky behaviors Preventative and cancer screenings Sexual and gynecologic health	Broad screening for substance use/abuse Screening individuals with SU for mental illness (e.g., schizophrenia) Sexual and gynecologic health	Broad screening for dementia Screening individuals with impairments for mental illness (e.g., depression) Cognitive functioning assessment Pain management Fall risk assessment	Functional status assessment Screening for SMIs Preventive cancer screening Sexual and gynecologic health

Common Issues Across High-Need Subgroups	SMI	SUD	Dementia/Acquired	ID/DD
	Engagement and counseling Affective disorders (e.g., major depression, bipolar disorders) Schizophrenia Paranoid disorders Illicit drug use Tobacco and alcohol use	Engagement and counseling Tobacco and alcohol use Illicit drug use	Dementia Alzheimer's disease Tobacco and alcohol use	Screening for SMIs



















65

Workgroup Charge for 2012/2013

- Identify opportunities to improve measurement for dual eligible beneficiaries.
- Determine the most suitable performance measures currently available, concentrating on high-need subgroups to include:
 - ^D Older adults with functional limitations and chronic conditions
 - Adults younger than 65 with physical disabilities
 - Individuals with serious mental illness
 - Individuals with cognitive impairment
- Document potential strategies to address measurement limitations.
- Delineate specific gaps in measures and available evidence to inform future measure development.
- Advise the Coordinating Committee on cross-cutting measurement issues and ensure alignment. These include MAP's strategic plan, families of measures, and pre-rulemaking input.



Evolving Core Measure Set for Dual Eligible Beneficiaries
--

NQF Measure Number/Status	Measure Name
NQF 0004 Endorsed	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
NQF 0022 Endorsed	Use of High-Risk Medications in the Elderly
NQF 0028 Endorsed	Tobacco Use Assessment and Tobacco Cessation Intervention
NQF 0097 Endorsed	Medication Reconciliation
NQF 0101 Time-Limited Endorsement	Screening for Fall Risk
NQF 0209 Endorsed	Comfortable Dying: Pain Brought to a Comfortable Level Within 48 Hours of Initial Assessment
NQF 0228 Endorsed	3-Item Care Transition Measure
NQF 0260 Endorsed	Assessment of Health-related Quality of Life [Physical and Mental Functioning]
NQF 0326 Endorsed	Advance Care Plan
NQF 0418 Endorsed	Screening for Clinical Depression
NQF 0420 Endorsed	Pain Assessment Prior to Initiation of Patient Therapy
NQF 0421 Endorsed	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
NQF 0430 Endorsed	Change in Daily Activity Function as Measured by the AM-PAC
NQF 0557 Endorsed	HBIPS-6 Post Discharge Continuing Care Plan Created
NQF 0558 Endorsed	HBIPS-7 Post Discharge Continuing Care Plan Transmitted to Next level of Care Provider Upon Discharge

Evolving Core Measure Set for Dual Eligible Beneficiaries

NQF Measure Number/Status	Measure Name
NQF 0576 Endorsed	Follow-up after Hospitalization for Mental Illness
NQF 0647 Endorsed	Transition Record with Specified Elements Received by Discharged Patients
NQF 0648 Endorsed	Timely Transmission of Transition Record
NQF 0729 Endorsed	Optimal Diabetes Care
NQF 1632 Endorsed	CARE – Consumer Assessments and Reports of End of Life
NQF 1626 Endorsed	Patients Admitted to ICU who Have Care Preferences Documented
NQF 1641 Endorsed	Hospice and Palliative Care – Treatment Preferences
NQF 1768 Endorsed	Plan All-Cause Readmissions
NQF 1789 Endorsed	Hospital-Wide All-Cause Unplanned Readmissions
NQF 1825 Endorsed	COPD – Management of Poorly Controlled COPD
NQF 1909 Endorsed	Medical Home System Survey
NQF 1919 Endorsed	Cultural Competency Implementation Measure
Multiple Surveys Endorsed	Consumer Assessment of Healthcare Providers and Systems (CAHPS) Surveys
Not Endorsed; to be added pending endorsement	Unhealthy Alcohol Use: Screening and Brief Counseling
Not Endorsed	SNP 6: Coordination of Medicare and Medicaid Coverage




ENDORSEMENT SUMMARY: Behavioral Health Measures

NOVEMBER 2012

Purpose of the Project

Behavioral health refers to a state of mental or emotional being and choices and actions that affect wellness, as defined by the Substance Abuse Mental Health Services Administration (SAMHSA). Behavioral health problems include substance abuse and misuse, alcohol and drug addiction, serious psychological distress, suicide, and mental and substance abuse disorders.

The World Health Organization estimates that more than 26 percent of the U.S. population suffers from mental illness and substance abuse. Within this group, six percent suffer from a serious mental illness. Many of these individuals – whose mental health status can dramatically impact how they engage with and respond to medical treatment – die 25 years earlier than the general population.¹

Given these troubling statistics, SAMHSA is now working to advance the National Behavioral Health Quality Framework, aimed at establishing national priorities, goals, and opportunities for improving the delivery of behavioral health services, achieving better behavioral health outcomes, and improving the behavioral health of the U.S. population, especially for those with mental illnesses and substance abuse. It is an example of how the broader National Quality Strategy has been tailored within a topic area of healthcare. Quality measurement is an essential component of this effort.

NQF has previously endorsed performance measures related to behavioral health, specifically focused on mental health and substance abuse. In November 2011, NQF – at the request of the Department of Health and Human Services – began a two-phase project aimed at endorsing new behavioral health measures applicable to all care delivery settings – including primary and specialty care – and capable of advancing the tenets of



NATIONAL QUALITY FORUM SAMHSA's quality framework.

The resulting endorsed measures are an important step forward in improving behavioral health services and care throughout the country.

What Was Endorsed

	Maintenance	New	Total
Measure submitted for consideration	4	18	22
Measures deferred	0	8	8
Measures withdrawn from consideration	0	3	3
Measures recommended for endorsement	4	6	10
Measures not recommended for endorsement	0	1	1

Under the behavioral health endorsement project, NQF endorsed 10 measures suitable for accountability and quality improvement. Of the 10 measures, four were previously endorsed and granted continued endorsement status, and six were newly submitted measures.

Measure stewards included a range of healthcare stakeholders, including the National Committee for Quality Assurance; the Physician Consortium for Performance Improvement, convened by the American Medical Association; and the Centers for Medicare & Medicaid Services. A full list of measures is available at the end of this report.

Summary of Behavioral Endorsement Maintenance Measures Project



The Need these Measures Fill

This project sought to identify and endorse measures that specifically address behavioral health services for accountability and quality improvement. The resulting measures focus on a wide range of care processes and services, including medical treatment for individuals experiencing new episodes of alcohol or other drug dependence; oral antipsychotic medication adherence for individuals diagnosed with schizophrenia; diabetes and cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications; and post care follow-up rates for hospitalized individuals with mental illness.

NQF has previously endorsed a small number of behavioral health measures, yet many measurement gaps remained. These new measures will help fill some of those gaps and give the healthcare community a significant opportunity to learn how to improve care for those suffering from mental illness and substance abuse.

Potential Use

These measures are applicable for use in a range of clinical settings and providers, which will help improve behavioral health quality across the healthcare spectrum. Settings include acute care hospitals, outpatient facilities, and physician offices.

Project Perspectives

With more than a quarter of the U.S. population suffering from some form of mental illness or substance abuse, efforts to measure and report on behavioral health treatment are critically important, and have the potential to dramatically improve the health and well-being of millions of individuals in this country. These measures will be key to helping the healthcare community achieve this aim.

NQF volunteer expert steering committee members identified several measurement gaps – as well as measures that could be harmonized – during their deliberations. Gaps in measurement include screening for alcohol and drugs, as well as screening for post-traumatic stress disorder and bipolar disorder in all patients diagnosed with depression. The steering committee hopes to address these measures gaps in phase 2 of the project, slated to kick off soon. The Centers for Medicare & Medicaid Services and the National Committee for Quality Assurance also worked together and successfully harmonized measures #1879 and #1936, focused on medication adherence for schizophrenic individuals and antipsychotic medication continuity for schizophrenia treatment, respectively. The committee also recommended that measure #1932 be harmonized with existing measure #0003 within the next 12 months, given their shared focus on diabetes screening for individuals with schizophrenia and bipolar disorder. These harmonized measures will help ease reporting burdens on providers.

Endorsed Measures

0004: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (NCQA)

Description: The percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) dependence who received the following:

- Initiation of AOD Treatment. The percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis.
- Engagement of AOD Treatment. The percentage of members who initiated treatment and who had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit.

0027: Medical Assistance With Smoking and Tobacco Use Cessation (NCQA)

Description: Assesses different facets of providing medical assistance with smoking and tobacco use cessation:

- Advising Smokers and Tobacco Users to Quit: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who received advice to quit during the measurement year.
- Discussing Cessation Medications: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were recommended cessation medications during the measurement year.

 Discussing Cessation Strategies: A rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were provided smoking cessation methods or strategies during the measurement year.

0028: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention (AMA-PCPI)

Description: Percentage of patients aged 18 years and older who were screened for tobacco use at least once during the two-year measurement period AND who received tobacco cessation counseling intervention if identified as a tobacco user.

1879: Adherence to Antipsychotic Medications for Individuals with Schizophrenia (CMS)

Description: The measure calculates the percentage of individuals 18 years of age or greater with schizophrenia who are prescribed an oral antipsychotic medication, with adherence to the antipsychotic medication [defined as a Proportion of Days Covered (PDC) of at least 0.8 during the measurement period (12 consecutive months).

1932: Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (SSD) (NCQA)

Description: The percentage of individuals 25 - 64 years of age with schizophrenia or bipolar disorder, who were prescribed any antipsychotic medication, and who received a diabetes screening during the measurement year.

1927: Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (NCQA)

Description: The percentage of individuals 25 - 64 years of age with schizophrenia or bipolar disorder who were prescribed any antipsychotic medication who received a cardiovascular health screening during the measurement year.

1933: Cardiovascular health monitoring for people with cardiovascular disease and schizophrenia (SMC) (NCQA)

Description: The percentage of individuals 25 - 64 years of age with a schizophrenia diagnosis and a diagnosis of cardiovascular disease who received

a cardiovascular health monitoring test (LDL-C) during the measurement year.

1934: Diabetes monitoring for people with diabetes and schizophrenia (NCQA)

Description: The percentage of individuals 25 – 64 years of age with schizophrenia and diabetes who received diabetes monitoring as specified by an HbA1c test and LDL-C test during the measurement year.

1937: Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (NCQA)

Description: The percentage of discharges for individuals 25 – 64 years of age who were hospitalized for treatment of schizophrenia and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported:

- The percentage of individuals who received follow-up within 30 days of discharge
- The percentage of individuals who received follow-up within 7 days of discharge

0576: Follow-Up After Hospitalization for Mental Illness (NCQA)

Description: This measure assesses the percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported:

Rate 1: The percentage of members who received follow-up within 30 days of discharge.

Rate 2: The percentage of members who received follow-up within 7 days of discharge.

Endnotes

1. Parks J, Radke A, Mazade NA, Measurement of Health Status for People with Serious Mental Illness. Alexandria, VA :National Association of State Mental Health Program Directors; 2008. Available at <u>www.nasmhpd.</u> org/general_files/publications/med_directors_pubs/ <u>NASMHPD%20Medical%20Directors%20Health%20</u> <u>Indicators%20Report%2011-19-08.pdf</u>. Last accessed October 2011.

Measure #	Title	Description	Developer
0103 0104	Major Depressive Disorder (MDD): Diagnostic Evaluation Major Depressive Disorder (MDD): Suicide Risk Assessment	Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who met the DSM-IV criteria during the visit in which the new diagnosis or recurrent episode was identified during the measurement period Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who had a suicide risk assessment completed at each visit during the measurement period	AMA-PCPI AMA-PCPI
0105	Antidepressant Medication Management	period The percentage of members 18 years of age and older who were diagnosed with a new episode of major depression and treated with antidepressant medication, and who remained on an antidepressant medication treatment. Two rates are reported. a) Effective Acute Phase Treatment. The percentage of newly diagnosed and treated members who remained on an antidepressant medication for at least 84 days (12 weeks). b) Effective Continuation Phase Treatment. The percentage of newly diagnosed and treated members who remained on an antidepressant medication for at least 180 days (6 months).	NCQA
0418	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	Percentage of patients aged 12 years and older screened for clinical depression on the date of encounter using an age appropriate standardized depression screening tool AND, if positive, a follow-up plan is documented on the date of the positive screen.	CMS / Quality Insights of PA
0518	Depression Assessment Conducted	Percent of patients who were screened for depression (using a standardized depression screening tool) at start or resumption of home health care	CMS/Acumen

Measure #	Title	Description	Developer
0552	HBIPS-4 Patients discharged on	Patients discharged on multiple antipsychotic medications overall and stratified by age groups:	The Joint Commision
	multiple	Children (Age 1 through 12 years), Adolescents	Commision
	antipsychotic	(Age 13 through 17 years), Adults (Age 18	
	medications	through 64 years), Older Adults (Age greater than	
		and equal to 65 years). Note: this is a paired	
		measure with HBIPS-5: Patients discharged on	
		multiple antipsychotic medications with	
		appropriate justification.	
0557	HBIPS-6 Post	Patients discharged from a hospital-based	The Joint
	discharge continuing	inpatient psychiatric setting with a continuing	Commision
	care plan created	care plan created overall and stratified by age	
		groups: Children (Age 1 through 12 years),	
		Adolescents (Age 13 through 17 years), Adults	
		(Age 18 through 64 years), Older Adults (Age	
		greater than and equal to 65 years). Note: this is	
		a paired measure with HBIPS-7: Post discharge	
		continuing care plan transmitted to next level of	
		care provider upon discharge.	
0558	HBIPS-7 Post	Patients discharged from a hospital-based	The Joint
	discharge continuing	inpatient psychiatric setting with a continuing	Commision
	care plan transmitted	care plan provided to the next level of care	
	to next level of care	clinician or entity overall and stratified by age	
	provider upon	groups: Children (Age 1 through 12 years),	
	discharge	Adolescents (Age 13 through 17 years), Adults	
		(Age 18 through 64 years), Older Adults (Age	
		greater than and equal to 65 years). Note: this is	
		a paired measure with HBIPS-6: Post discharge	
0560	HBIPS-5 Patients	continuing care plan created. Patients discharged from a hospital-based	The Joint
0300	discharged on	inpatient psychiatric setting on two or more	Commision
	multiple	antipsychotic medications with appropriate	COMMISION
	antipsychotic	justification overall and stratified by age groups:	
	medications with	Children (Age 1 through 12 years), Adolescents	
	appropriate	(Age 13 through 17 years), Adults (Age 18	
	justification	through 64 years), Older Adults (Age greater than	
	,	and equal to 65 years). Note: this is a paired	
		measure with HBIPS-4: Patients discharged on	
		multiple antipsychotic medications.	

Measure #	Title	Description	Developer
0640	HBIPS-2 Hours of physical restraint use	The number of hours that all patients admitted to a hospital-based inpatient psychiatric setting were maintained in physical restraint per 1000 psychiatric inpatient hours, overall and stratified by age groups: : Children (Age 1 through 12 years), Adolescents (Age 13 through 17 years), Adults (Age 18 through 64 years), Older Adults (Age greater than and equal to 65 years).	The Joint Commision
0641	HBIPS-3 Hours of seclusion use	The number of hours that all patients admitted to a hospital-based inpatient psychiatric setting were held in seclusion per 1000 psychiatric inpatient hours, overall and stratified by age groups:Children (Age 1 through 12 years), Adolescents (Age 13 through 17 years), Adults (Age 18 through 64 years), Older Adults (Age greater than and equal to 65 years).	The Joint Commision
1651	TOB-1 Tobacco Use Screening	Hospitalized patients age 18 years and older who are screened during the hospital stay for tobacco use (cigarettes, smokeless tobacco, pipe and cigars) within the past 30 days. This measure is intended to be used as part of a set of 4 linked measures addressing Tobacco Use (TOB-2 Tobacco Use Treatment Provided or Offered (during the hospital stay); TOB-3 Tobacco Use Treatment Provided or offered at Discharge; TOB- 4 Tobacco Use: Assessing Status After Discharge.)	The Joint Commision
1654	TOB - 2 Tobacco Use Treatment Provided or Offered and the subset measure TOB- 2a Tobacco Use Treatment	The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom tobacco use treatment was provided during the hospital stay, or offered and refused, and a second rate, a subset of the first, which includes only those patients who received tobacco use treatment during the hospital stay. Refer to section 2a1.10 Stratification Details/Variables for the rationale for the addition of the subset measure. These measures are intended to be used as part of a set of 4 linked measures addressing Tobacco Use (TOB-1 Tobacco Use Screening; TOB-3 Tobacco Use Treatment Provided or Offered at Discharge; TOB-4 Tobacco Use: Assessing Status After Discharge.)	The Joint Commision

Measure #	Title	Description	Developer
1656	TOB-3 Tobacco Use	The measure is reported as an overall rate which	The Joint
	Treatment Provided	includes all hospitalized patients 18 years of age	Commision
	or Offered at	an older to whom tobacco use treatment was	
	Discharge and the	provided, or offered and refused, at the time of	
	subset measure TOB-	hospital discharge, and a second rate, a subset of	
	3a Tobacco Use	the first, which includes only those patients who	
	Treatment at	received tobacco use treatment at discharge.	
	Discharge	Treatment at discharge includes a referral to	
		outpatient counseling and a prescription for one	
		of the FDA-approved tobacco cessation	
		medications. Refer to section 2a1.10	
		Stratification Details/Variables for the rationale	
		for the addition of the subset measure. These	
		measures are intended to be used as part of a set	
		of 4 linked measures addressing Tobacco Use (TOB-1 Tobacco Use Screening; TOB 2 Tobacco	
		Use Treatment Provided or Offered During the	
		Hospital Stay; TOB-4 Tobacco Use: Assessing	
		Status After Discharge).	
1657	TOB-4 Tobacco Use:	Hospitalized patients 18 years of age and older	The Joint
1007	Assessing Status after	who are identified through the screening process	Commision
	Discharge	as having used tobacco products (cigarettes,	•••••
		smokeless tobacco, pipe, and cigars) within the	
		past 30 days who are contacted between 15 and	
		30 days after hospital discharge and follow-up	
		information regarding tobacco use status is	
		collected. This measure is intended to be used as	
		part of a set of 4 linked measures addressing	
		Tobacco Use (TOB-1 Tobacco Use Screening; TOB-	
		2 Tobacco Use Treatment Provided or Offered	
		(during hospital stay); TOB-3 Tobacco Use	
		Treatment Provided or Offered at Discharge.	
1661	SUB-1 Alcohol Use	Hospitalized patients 18 years of age and older	The Joint
	Screening	who are screened during the hospital stay using a	Commision
		validated screening questionnaire for unhealthy	
		alcohol use. This measure is intended to be used	
		as part of a set of 4 linked measures addressing	
		Substance Use (SUB-1 Alcohol Use Screening ;	
		SUB-2 Alcohol Use Brief Intervention Provided or	
		Offered; SUB-3 Alcohol and Other Drug Use	
		Disorder Treatment Provided or Offered at	
		Discharge; SUB-4 Alcohol and Drug Use: Assessing	
		Status after Discharge).	

Measure #	Title	Description	Developer
1663	SUB-2 Alcohol Use	The measure is reported as an overall rate which	The Joint
	Brief Intervention	includes all hospitalized patients 18 years of age	Commision
	Provided or Offered	and older to whom a brief intervention was	
	and SUB-2a Alcohol	provided, or offered and refused, and a second	
	Use Brief	rate, a subset of the first, which includes only	
	Intervention	those patients who received a brief intervention.	
		The Provided or Offered rate (SUB-2), describes	
		patients who screened positive for unhealthy	
		alcohol use who received or refused a brief	
		intervention during the hospital stay. The Alcohol	
		Use Brief Intervention (SUB-2a) rate describes	
		only those who received the brief intervention	
		during the hospital stay. Those who refused are	
		not included.	
		These measures are intended to be used as part	
		of a set of 4 linked measures addressing	
		Substance Use (SUB-1 Alcohol Use Screening ;	
		SUB-2 Alcohol Use Brief Intervention Provided or	
		Offered; SUB-3 Alcohol and Other Drug Use	
		Disorder Treatment Provided or Offered at	
		Discharge; SUB-4 Alcohol and Drug Use: Assessing	
		Status after Discharge).	

Measure #	Title	Description	Developer
1664	SUB-3 Alcohol &	The measure is reported as an overall rate which	The Joint
	Other Drug Use	includes all hospitalized patients 18 years of age	Commision
	Disorder Treatment	and older to whom alcohol or drug use disorder	
	Provided or Offered	treatment was provided, or offered and refused,	
	at Discharge and	at the time of hospital discharge, and a second	
	SUB-3a Alcohol &	rate, a subset of the first, which includes only	
	Other Drug Use	those patients who received alcohol or drug use	
	Disorder Treatment	disorder treatment at discharge. The Provided or	
	at Discharge	Offered rate (SUB-3) describes patients who are	
		identified with alcohol or drug use disorder who	
		receive or refuse at discharge a prescription for	
		FDA-approved medications for alcohol or drug	
		use disorder, OR who receive or refuse a referral	
		for addictions treatment. The Alcohol and Other	
		Drug Disorder Treatment at Discharge (SUB-3a)	
		rate describes only those who receive a	
		prescription for FDA-approved medications for	
		alcohol or drug use disorder OR a referral for	
		addictions treatment. Those who refused are not	
		included.	
		These measures are intended to be used as part	
		of a set of 4 linked measures addressing	
		Substance Use (SUB-1 Alcohol Use Screening ;	
		SUB-2 Alcohol Use Brief Intervention Provided or	
		Offered; SUB-3 Alcohol and Other Drug Use	
		Disorder Treatment Provided or Offered at	
		Discharge; SUB-4 Alcohol and Drug Use: Assessing	
1005	CLID 4 Alashal 8 Dava	Status after Discharge).	The Joint
1665	SUB-4 Alcohol & Drug Use: Assessing Status	Hospitalized patients age 18 years and older who	Commision
	After Discharge	screened positive for unhealthy alcohol use or who received a diagnosis of alcohol or drug	COMMISSION
	Alter Discharge	disorder during their inpatient stay, who are	
		contacted between 7 and 30 days after hospital	
		discharge and follow-up information regarding	
		their alcohol or drug use status post discharge is	
		collected.	
		This measure is intended to be used as part of a	
		•	
		C	
		Status after Discharge).	
		,,	
		set of 4 linked measures addressing Substance Use (SUB-1) Alcohol Use Screening ; SUB-2 Alcohol Use Brief Intervention Provided or Offered; SUB-3 Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge; SUB-4 Alcohol and Drug Use: Assessing Status after Discharge).	

Measure #	Title	Description	Developer
1880	Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder	The measure calculates the percentage of individuals 18 years of age or greater as of the beginning of the measurement period with bipolar I disorder who are prescribed a mood stabilizer medication, with adherence to the mood stabilizer medication [defined as a Proportion of Days Covered (PDC)] of at least 0.8 during the measurement period (12 consecutive months).	CMS/ FMQAI
1884	Depression Response at Six Months- Progress Towards Remission	Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate a response to treatment at six months defined as a PHQ-9 score that is reduced by 50% or greater from the initial PHQ-9 score. This measure applies to both patients with newly diagnosed and existing depression identified during the defined measurement period whose current PHQ-9 score indicates a need for treatment.	MN Community Measurement
1885	Depression Response at Twelve Months - Progress Towards Remission	Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate a response to treatment at twelve months defined as a PHQ-9 score that is reduced by 50% or greater from the initial PHQ-9 score. This measure applies to both patients with newly diagnosed and existing depression identified during the defined measurement period whose current PHQ-9 score indicates a need for treatment.	MN Community Measurement
1922	HBIPS-1 Admission Screening	The proportion of patients admitted to a hospital- based inpatient psychiatric setting who are screened within the first three days of hospitalization for all of the following: risk of violence to self or others, substance use, psychological trauma history and patient strengths. This measure is a part of a set of seven nationally implemented measures that address hospital-based inpatient psychiatric services (HBIPS-2: Physical Restraint, HBIPS-3: Seclusion, HBIPS-4: Multiple Antipsychotic Medications at Discharge, HBIPS-5: Multiple Antipsychotic Medications at Discharge with Appropriate Justification, HBIPS-6: Post Discharge Continuing Care Plan and HBIPS-7: Post Discharge Continuing Care Plan Transmitted) that are used in The Joint Commission's accreditation process.	The Joint Commision

Measure #	Title	Description	Developer
1923	Severity-adjusted	This measure estimates a Severity-Adjusted Effect	Optum Health
	Effect Size Measure	Size (SAES) of change in behavioral health	
	for Adult Behavioral	symptoms and functioning among adult patients	
	Health Symptoms	(18 years and older) receiving outpatient	
	and Functioning	behavioral health services. The SAES is estimated	
		for behavioral health providers ('provider' refers	
		to individual behavioral health clinicians or group	
		practices).	
		The SAES is derived through four steps:	
		1. Change in behavioral health symptoms and	
		functioning is measured using the Global Distress	
		Scale (GDS) of the Wellness Assessment (WA)	
		during an episode of outpatient behavioral health	
		treatment. The WA is administered to adult	
		patients at the onset of behavioral health	
		treatment episode ("baseline") and at least once more within six months ("follow-up"). A	
		treatment episode change score is calculated by	
		subtracting the baseline GDS score from the	
		follow-up GDS score.	
		2. The treatment episode change score is then	
		severity-adjusted using general linear modeling	
		to account for the patients' clinical	
		characteristics. To derive the residualized change	
		score, the actual change score is subtracted from	
		severity-adjusted change score.	
		3. A population effect size is calculated and then	
		added to each episode's residualized effect size.	
		This represents the episode-level severity-	
		adjusted effect size.	
		4. Hierarchical linear modeling (HLM) is used to	
		create a provider-level Severity Adjusted Effect	
		Size (SAES) and associated confidence interval.	
2152	Preventive Care and	Percentage of patients aged 18 years and older	AMA-PCPI
	Screening: Unhealthy	who were screened for unhealthy alcohol use at	
	Alcohol Use:	least once during the two-year measurement	
	Screening & Brief	period using a systematic screening method AND	
	Counseling	who received brief counseling if identified as an	
		unhealthy alcohol user	

Proposed Key Issues for Measurement in High-Need Subgroups of Dual Eligible Beneficiaries: Serious Mental Illness (SMI), Substance Use Disorder (SUD), Dementia and Other Acquired Impairments, and Intellectual/Developmental Disabilities (ID/DD)

High-Leverage Opportunities	Common Issues Across High-Need Subgroups	Serious Mental Illness	Substance Use Disorders	Dementia/Acquired Impairments	Intellectual and Developmental Disabilities
Quality of Life	Preventing abuse and neglect (specifically in institutional settings) Maintaining or improving functional status Shared decision- making Respect for personal preferences	Improving personal independence and self- direction	Withdrawal management Maintaining or improving functional status Decision support/shared- decision making	Rehabilitation and redevelopment of functional skills Improving or maintaining personal independence and self-direction Social engagement and involvement in meaningful activities	Habilitation and development of key functional and personal skills Engagement and participation in healthy activities Improving or maintaining personal independence and self-direction Physical accessibility and mobility Maintaining or improving functional status
Care Coordination and Safety	Avoidable admissions, readmissions, complications Person-centered care planning Care transitions, discharge planning Communication between providers Communication between providers and beneficiaries Cultural competence Medication management: access, appropriateness, reconciliation, adherence Adverse drug events	Use of physical restraints Suicide prevention	Suicide prevention	Use of physical restraints Advance care planning	Use of physical restraints

Measure Applications Partnership: Dual Eligible Beneficiaries Workgroup Web Meeting on April 30, 2013 Proposed Key Issues for Measurement in High-Need Subgroups of Dual Eligible Beneficiaries: Serious Mental Illness (SMI), Substance Use Disorder (SUD), Dementia and Other Acquired Impairments, and Intellectual/Developmental Disabilities (ID/DD)

High-Leverage Opportunities	Common Issues Across High-Need Subgroups	Serious Mental Illness	Substance Use Disorders	Dementia/Acquired Impairments	Intellectual and Developmental Disabilities
Screening and Assessment	Oral Health Nutrition and weight management New or worsening chronic conditions, especially cardio- metabolic diseases	Broad screening for SMIs Screening for substance use and/or risky behaviors Preventative and cancer screenings Sexual and gynecologic health	Broad screening for substance use/abuse Screening individuals with SU for mental illness (e.g., schizophrenia) Sexual and gynecologic health	Broad screening for dementia Screening individuals with impairments for mental illness (e.g., depression) Cognitive functioning assessment Pain management Fall risk assessment	Functional status assessment Screening for SMIs Preventive cancer screening Sexual and gynecologic health
Mental Health and Substance Use		Engagement and counseling Affective disorders (e.g., major depression, bipolar disorders) Schizophrenia Paranoid disorders Illicit drug use Tobacco and alcohol use	Engagement and counseling Tobacco and alcohol use Illicit drug use	Dementia Alzheimer's disease Tobacco and alcohol use	Screening for SMIs
Structural Measures	Access to needed services (e.g., health home, primary care, specialty care, dental care, vision care, durable medical equipment, habilitation, rehabilitation, occupational therapy, community mental health providers) Workforce adequacy, stability, and training Providers' linkages to community resources (e.g., special education, human services, transportation) Formal caregiver support Informal caregiver support Cultural competency Monitoring referrals				

Measure Applications Partnership: Dual Eligible Beneficiaries Workgroup Web Meeting on April 30, 2013